Transcriptomic signatures of progression to TB disease among close contacts in Brazil

Simon C Mendelsohn,Bruno B Andrade,Stanley Kimbung Mbandi,Alice M S Andrade,Vanessa M Muwanga,Marina C Figueiredo,Mzwandile Erasmus,Valeria C Rolla,Prisca K Thami,Marcelo Cordeiro-Santos,Adam Penn-Nicholson,Afranio L Kritski,Mark Hatherill,Timothy R Sterling,Thomas J Scriba,Nicole Bilek,Yolundi Cloete,Mzwandile Erasmus,Michelle Fisher,Katie Hadley,Rieyaat Hassiem,Mark Hatherill,Lungisa Jaxa,Stanley Kimbung Mbandi,Simon C Mendelsohn,Faheemah Meyer,Vanessa M Muwanga,Onke Nombida,Adam Penn-Nicholson,Rodney Raphela,Thomas J Scriba,Alison September,Timothy R Sterling,Prisca K Thami,Ashley Veldsman,Alice Andrade,Bruno B Andrade,Brenda Carvalho,Marcelo Cordeiro-Santos,Marina Cruvinel Figueiredo,Adriano Gomes,Afranio L Kritski,Valeria C Rolla,Timothy R Sterling,the RePORT-South Africa and RePORT-Brazil Consortia

DOI: https://doi.org/10.1093/infdis/jiae237

2024-05-07

The Journal of Infectious Diseases

Abstract:Background Approximately 5% of people infected with Mycobacterium tuberculosis progress to tuberculosis (TB) disease without preventive therapy. There is a need for a prognostic test to identify those at highest risk of incident TB, so that therapy can be targeted. We evaluated host blood transcriptomic signatures for progression to TB disease. Methods Close contacts (≥4 hours exposure per week) of adult patients with culture-confirmed pulmonary TB were enrolled in Brazil. Investigation for incident, microbiologically-confirmed or clinically-diagnosed pulmonary or extra-pulmonary TB disease through 24 months of follow-up was symptom-triggered. Twenty previously validated blood TB transcriptomic signatures were measured at baseline by real-time quantitative PCR. Prognostic performance for incident TB was tested using receiver operating characteristic curve (ROC) analysis at 6, 9, 12, and 24 months of follow-up. Results Between June 2015 and June 2019, 1,854 close contacts were enrolled; Twenty-five progressed to incident TB, of whom 13 had microbiologically-confirmed disease. Baseline transcriptomic signature scores were measured in 1,789 close contacts. Prognostic performance for all signatures was best within 6 months of diagnosis. Seven signatures (Gliddon4, Suliman4, Roe3, Roe1, Penn-Nicholson6, Francisco2, and Rajan5) met the minimum World Health Organization target product profile (TPP) for a prognostic test through 6 months; three (Gliddon4, Rajan5, and Duffy9) through 9 months. None met the TPP threshold through 12 or more months of follow-up. Conclusions Blood transcriptomic signatures may be useful for predicting TB risk within 9 months of measurement among TB-exposed contacts, to target preventive therapy administration.

immunology,infectious diseases,microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a biomarker test capable of predicting the risk of tuberculosis (TB) progression. Specifically, the researchers evaluated the transcriptomic features in the blood to identify high - risk individuals who are most likely to develop active tuberculosis after exposure to Mycobacterium tuberculosis, so that preventive treatment can be implemented more precisely. Currently, although there are some clinical factors that can increase the risk of tuberculosis, there is a lack of tests that can accurately predict which people will develop active tuberculosis in the short term. This has led to unnecessary treatment and waste of resources. Therefore, the goal of this study is to improve the ability to predict the risk of tuberculosis progression by analyzing the transcriptomic features in the host blood, especially for those who are in close contact with tuberculosis patients.

The main contributions of the study are as follows:
- **Evaluating transcriptomic features**: The researchers evaluated 20 previously validated blood transcriptomic features, which were measured by real - time quantitative PCR at baseline for predicting the progression of tuberculosis.
- **Predictive performance**: The study found that 7 transcriptomic features met the World Health Organization (WHO) minimum target product profile (TPP) criteria within 6 months, and 3 features met the criteria within 9 months. However, no features met the criteria within 12 months or longer.
- **Geographical universality**: The consistency of the research results in the Brazilian population indicates that these transcriptomic features may not be affected by population genetic differences and have geographical universality.

In conclusion, this study aims to improve the prediction accuracy of the risk of tuberculosis progression by identifying effective biomarkers, thereby optimizing the use of preventive treatment.